Classic Galactosemia

For the why behind the fact

Use this page to connect what you are memorizing.

Start with the overview when a class slide, Anki card, or qbank explanation feels too thin. Then use presentation and workup to recognize the condition, and differentials to separate look-alikes.

Overview


Plain-Language Overview

A baby with classic galactosemia cannot process galactose normally. Breast milk and standard milk formula contain lactose, which releases galactose during digestion. Within days, a newborn may feed poorly, vomit, turn yellow or develop a serious bloodstream infection. Prompt replacement with a suitable infant formula helps prevent acute liver failure. Speech, movement or reproductive problems can still develop despite early treatment.

Clinical Definition

Classic galactosemia is autosomal recessive deficiency of galactose-1-phosphate uridylyltransferase (GALT). After lactose feeding, galactose-1-phosphate accumulates and surplus galactose is reduced to galactitol. Think of a newborn with jaundice, hepatomegaly, poor feeding and E. coli sepsis. Galactitol draws water into the lens and can cause cataracts. Feeding changes are urgent while confirmation is pending.

Inciting Event

  • Introduction of galactose-containing milk or formula triggers symptom onset.

  • Exposure to lactose in breast milk or cow’s milk formula initiates toxic metabolite accumulation.

  • Failure to metabolize galactose after birth leads to rapid clinical deterioration.

Latency Period

  • Severe illness may begin within days of starting breast milk or standard lactose-containing formula.

  • Clinical signs appear rapidly as toxic metabolites accumulate in tissues.

  • Delay in symptom onset beyond neonatal period is uncommon in classic galactosemia.

Diagnostic Delay

  • Early symptoms such as jaundice and vomiting are nonspecific and often attributed to common neonatal conditions.

  • Lack of routine newborn screening in some areas delays diagnosis.

  • E. coli sepsis can be the first clue to classic galactosemia. A positive culture should prompt treatment of infection alongside evaluation of milk-triggered liver injury.

  • Failure to recognize the significance of feeding intolerance and hepatomegaly in neonates.

Clinical Presentation


Signs & Symptoms

  • Vomiting and diarrhea shortly after milk ingestion

  • Jaundice and hepatomegaly in the neonatal period

  • Cataracts developing within the first few weeks of life

  • Lethargy and hypotonia indicating central nervous system involvement

  • Lethargy, poor feeding or temperature instability may indicate true neonatal sepsis, classically due to E. coli.

History of Present Illness

  • Onset of poor feeding, vomiting, and lethargy within days to weeks after starting milk feeding.

  • Development of jaundice, hepatomegaly, and failure to thrive in the neonatal period.

  • A newborn may develop hypoglycemia, coagulopathy and E. coli bacteremia during the same illness.

  • Infants may exhibit cataracts and hypotonia as disease progresses without treatment.

Past Medical History

  • Typically no prior medical history as symptoms begin in the neonatal period.

  • Absence of prior illnesses but history of feeding with lactose-containing formula or breast milk is critical.

  • No history of metabolic disorders unless previously diagnosed in siblings.

Family History

  • Presence of siblings with similar neonatal illness or early death suggests autosomal recessive inheritance.

  • Known family history of classic galactosemia or carrier status in parents.

  • Consanguinity or ethnic background with higher prevalence increases suspicion.

Physical Exam Findings

  • Jaundice with scleral icterus due to hepatic dysfunction

  • Hepatomegaly from liver inflammation and damage

  • Cataracts visible on slit-lamp examination in infants

  • Failure to thrive with poor weight gain and growth retardation

  • Hypotonia and developmental delay in untreated cases

Diagnostic Workup


Diagnostic Criteria

A positive newborn screen requires urgent metabolic evaluation. Confirm with markedly reduced or absent erythrocyte GALT activity, erythrocyte galactose-1-phosphate and/or two pathogenic GALT variants in trans. A recent red-cell transfusion may mask deficient enzyme activity. Give the laboratory the transfusion and feeding history, and use specialist-directed molecular testing when needed.

Pathophysiology


Key Mechanisms

  • GALT normally transfers a uridylyl group from UDP-glucose to galactose-1-phosphate, forming UDP-galactose and glucose-1-phosphate. Loss of this step increases galactose-1-phosphate.

  • Accumulation of galactitol via aldose reductase causes osmotic damage in lens and other tissues.

  • Impaired galactose metabolism disrupts energy production and cellular function in liver, brain, and kidneys.

  • Toxic metabolites cause hepatocellular injury, leading to jaundice and hepatomegaly.

  • Accumulation of galactose metabolites in the brain contributes to intellectual disability and neurologic deficits.

InvolvementDetails
Organs

Liver is the primary organ affected, showing hepatomegaly, jaundice, and potential liver failure.

Eyes develop cataracts due to galactitol accumulation in the lens.

Brain involvement leads to intellectual disability and motor dysfunction in untreated patients.

Tissues

Liver tissue is damaged by toxic metabolite accumulation leading to hepatomegaly, jaundice, and fibrosis.

Lens tissue undergoes osmotic swelling and damage resulting in cataracts.

Brain tissue may show developmental abnormalities and neuronal loss contributing to cognitive impairment.

Cells

Hepatocytes are critically affected due to accumulation of toxic galactose-1-phosphate causing liver dysfunction.

Lens epithelial cells accumulate galactitol leading to osmotic damage and formation of cataracts.

Neurons may be damaged by toxic metabolites contributing to long-term neurological deficits.

Chemical Mediators

Galactose-1-phosphate accumulates due to deficient galactose-1-phosphate uridyltransferase activity, causing cellular toxicity.

Galactitol accumulates in the lens, causing osmotic stress and cataract formation.

The block disrupts UDP-sugar metabolism. Mechanisms of persistent neurologic and ovarian complications are incompletely understood.

Treatments


Pharmacological Treatments

No disease-specific pharmacological treatment is listed for this topic.

Non-pharmacological Treatments

  • On suspicion, stop breast milk and standard lactose-containing formula immediately. Start an appropriate galactose-restricted infant formula such as soy infant formula with urgent metabolic-team guidance, before confirmatory results.

  • Supportive management of complications such as cataracts and liver dysfunction with appropriate specialist care.

  • Regular monitoring of growth, development, and neurological status to guide supportive interventions.

Prevention


Pharmacological Prevention

  • No established pharmacological prophylaxis exists for classic galactosemia

  • Dietary treatment is the standard intervention. Evaluate acute complications and treat infections promptly.

  • Assess calcium and vitamin D intake during dairy restriction and supplement when intake or measured status is inadequate.

Non-pharmacological Prevention

  • Newborn screening for early detection of GALT deficiency

  • Continue lifelong restriction of major dairy galactose sources. Fruits, vegetables and legumes are generally permitted.

  • For infants, use a metabolic-team-approved nutritionally complete formula. Ordinary plant beverages are unsuitable substitutes for infant formula.

  • Genetic counseling for families with known GALT mutations

  • Regular monitoring of growth, development, and organ function to prevent complications

Outcome & Complications


Complications

  • Liver failure from progressive hepatic damage

  • E. coli sepsis can accompany acute liver disease. Obtain cultures and start empiric neonatal sepsis treatment promptly in an ill newborn.

  • Cataract formation causing visual impairment

  • Neurological impairment including intellectual disability and ataxia

  • Primary ovarian insufficiency is common in affected females even with early treatment. Fertility is reduced, but spontaneous pregnancy can occur.

Short-term Sequelae Long-term Sequelae
  • Acute liver dysfunction with jaundice and coagulopathy

  • Hypoglycemia due to impaired gluconeogenesis

  • Sepsis and systemic infection in the neonatal period

  • Electrolyte imbalances from vomiting and diarrhea

  • Feeding intolerance and failure to thrive

  • Cognitive impairment and learning disabilities despite dietary management

  • Speech and motor developmental delays

  • Monitor pubertal development and ovarian function. Offer individualized reproductive counseling because ovarian insufficiency does not invariably mean sterility.

  • Osteopenia or osteoporosis due to chronic metabolic effects

  • Chronic neurological symptoms such as tremor and ataxia

Differential Diagnoses


Classic Galactosemia versus Hereditary Fructose Intolerance

Classic Galactosemia

Hereditary Fructose Intolerance

Symptoms triggered by ingestion of galactose or lactose-containing foods

Symptoms triggered by ingestion of fructose, sucrose, or sorbitol

Elevated galactose-1-phosphate in erythrocytes and tissues

Aldolase B deficiency traps phosphate as intracellular fructose-1-phosphate and impairs glycogenolysis and gluconeogenesis, causing hypoglycemia after fructose exposure.

Very low erythrocyte GALT activity and/or biallelic pathogenic GALT variants establish the cause.

Biallelic pathogenic ALDOB variants confirm hereditary fructose intolerance. Avoid a diagnostic fructose challenge.

Classic Galactosemia versus Neonatal Sepsis

Classic Galactosemia

Neonatal Sepsis

Poor feeding and liver injury typically follow milk exposure within days.

Neonatal sepsis can occur during this same period and may complicate galactosemia.

Low erythrocyte GALT and high erythrocyte galactose-1-phosphate support the metabolic diagnosis even with a positive blood culture.

Culture can identify invasive bacteria. E. coli bacteremia in a jaundiced milk-fed newborn strengthens concern for galactosemia.

Replace lactose-containing feeds immediately and treat suspected sepsis concurrently.

Start empiric antibiotics promptly after obtaining cultures when feasible. Infection treatment alone leaves the dietary trigger in place.

Classic Galactosemia versus Galactokinase Deficiency

Classic Galactosemia

Galactokinase Deficiency

Erythrocyte galactose-1-phosphate rises and urinary galactitol can be elevated.

The upstream galactokinase block limits galactose-1-phosphate formation. Galactose and galactitol rise while GALT activity is preserved.

Cataracts may accompany severe liver disease and E. coli sepsis.

Cataracts often dominate in galactokinase deficiency, with the infant otherwise well.

Deficiency of GALT enzyme activity

Deficiency of galactokinase enzyme activity

Classic Galactosemia versus Tyrosinemia Type I

Classic Galactosemia

Tyrosinemia Type I

Elevated galactose-1-phosphate and galactitol without succinylacetone

Elevated blood or urine succinylacetone is the characteristic marker. Tyrosine alone is nonspecific.

Milk-triggered hepatic injury, cataracts or E. coli sepsis suggest GALT deficiency. Renal tubular dysfunction can also occur.

Renal tubular dysfunction and rickets along with liver failure

Deficiency of GALT enzyme activity

Confirm with elevated succinylacetone and/or biallelic pathogenic FAH variants.

Classic Galactosemia versus Crigler-Najjar Syndrome

Classic Galactosemia

Crigler-Najjar Syndrome

Elevated galactose-1-phosphate with mixed hyperbilirubinemia

Isolated unconjugated hyperbilirubinemia with normal galactose metabolites

Milk-triggered liver disease may include conjugated jaundice, coagulopathy and true sepsis.

Severe jaundice and risk of kernicterus without liver failure or sepsis

Deficiency of GALT enzyme activity

The isolated unconjugated bilirubin pattern suggests impaired conjugation; UGT1A1 molecular testing can confirm the cause.